Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
Business Insider on MSN8d
See ya, knock-off OzempicLots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
On December 19, 2024, FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly is tirzepatide’s patentholder and the ...
What is the generic name for Zepbound? The generic name of the active ingredient in Zepbound is tirzepatide. However, Zepbound is not available to buy as a generic drug for weight loss.
More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.
Tirzepatide, however ... Plus, he says, people who buy weight loss medications on the cheap aren’t typically getting the nutritional counseling to ensure that they’re staying healthy when ...
In summary, Citi analysts believe that 2025 is shaping up to be another blockbuster year for Eli Lilly, reiterating their Buy rating and $1,250 price target on the stock. The confidence is based on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback